CHRS Long Call Strategy
CHRS (Coherus Oncology, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances.
CHRS (Coherus Oncology, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $183.6M, a beta of 0.96 versus the broader market, a 52-week range of 0.72-2.616, average daily share volume of 1.1M, a public-listing history dating back to 2014, approximately 228 full-time employees. These structural characteristics shape how CHRS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.96 places CHRS roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long call on CHRS?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current CHRS snapshot
As of June 30, 2026, spot at $1.42, ATM IV 214.30%, IV rank 49.30%, expected move 61.44%. The long call on CHRS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long call structure on CHRS specifically: CHRS IV at 214.30% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 61.44% (roughly $0.87 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CHRS expiries trade a higher absolute premium for lower per-day decay. Position sizing on CHRS should anchor to the underlying notional of $1.42 per share and to the trader's directional view on CHRS stock.
CHRS long call setup
The CHRS long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CHRS near $1.42, the first option leg uses a $1.42 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CHRS chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CHRS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.42 | N/A |
CHRS long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
CHRS long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on CHRS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on CHRS
Long calls on CHRS express a bullish thesis with defined risk; traders use them ahead of CHRS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
CHRS thesis for this long call
The market-implied 1-standard-deviation range for CHRS extends from approximately $0.55 on the downside to $2.29 on the upside. A CHRS long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current CHRS IV rank near 49.30% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on CHRS should anchor more to the directional view and the expected-move geometry. As a Healthcare name, CHRS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CHRS-specific events.
CHRS long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CHRS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CHRS alongside the broader basket even when CHRS-specific fundamentals are unchanged. Long-premium structures like a long call on CHRS are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CHRS chain quotes before placing a trade.
Frequently asked questions
- What is a long call on CHRS?
- A long call on CHRS is the long call strategy applied to CHRS (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With CHRS stock trading near $1.42, the strikes shown on this page are snapped to the nearest listed CHRS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CHRS long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the CHRS long call priced from the end-of-day chain at a 30-day expiry (ATM IV 214.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CHRS long call?
- The breakeven for the CHRS long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CHRS market-implied 1-standard-deviation expected move is approximately 61.44%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on CHRS?
- Long calls on CHRS express a bullish thesis with defined risk; traders use them ahead of CHRS catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current CHRS implied volatility affect this long call?
- CHRS ATM IV is at 214.30% with IV rank near 49.30%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.